![A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer]()
A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancerDrilon, A.; Somwar, R.; Wagner, J. P.; Vellore, N. A.; Eide, C. A.; Zabriskie, M. S.; Arcila, M. E.; Hechtman, J. F.; Wang, L.; Smith, R. S.; Kris, M. G.; Riely, G. J.; Druker, B. J.; O'Hare, T.; Ladanyi, M.; Davare, M. A. · Clinical Cancer Research · 2015